Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trialJonas Bergh, Nils Wilking, Henrik Lindman et al.|The Lancet|2000Cited by 343
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyNils Wilking, Jonas Bergh, Elisabet Lidbrink et al.|Annals of Oncology|2007Cited by 36